Skip to main content
Top
Published in: Breast Cancer Research 5/2007

Open Access 01-10-2007 | Research article

Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004

Authors: Theresa HM Keegan, Ellen T Chang, Esther M John, Pamela L Horn-Ross, Margaret R Wrensch, Sally L Glaser, Christina A Clarke

Published in: Breast Cancer Research | Issue 5/2007

Login to get access

Abstract

Introduction

Historically, the incidence rate of breast cancer among non-Hispanic white women living in the San Francisco Bay area (SFBA) of California has been among the highest in the world. Substantial declines in breast cancer incidence rates have been documented in the United States and elsewhere during recent years. In light of these reports, we examined recent changes in breast cancer incidence and risk factor prevalence among non-Hispanic white women in the SFBA and other regions of California.

Methods

Annual age-adjusted breast cancer incidence and mortality rates (1988 to 2004) were obtained from the California Cancer Registry and analyzed using Joinpoint regression. Population-based risk factor prevalences were calculated using two data sources: control subjects from four case-control studies (1989 to 1999) and the 2001 and 2003 California Health Interview Surveys.

Results

In the SFBA, incidence rates of invasive breast cancer increased 1.3% per year (95% confidence interval [CI], 0.7% to 2.0%) in 1988–1999 and decreased 3.6% per year (95% CI, 1.6% to 5.6%) in 1999–2004. In other regions of California, incidence rates of invasive breast cancer increased 0.8% per year (95% CI, 0.4% to 1.1%) in 1988–2001 and decreased 4.4% per year (95% CI, 1.4% to 7.3%) in 2001–2004. In both regions, recent (2000–2001 to 2003–2004) decreases in invasive breast cancer occurred only in women 40 years old or older and in women with all histologic subtypes and tumor sizes, hormone receptor-defined types, and all stages except distant disease. Mortality rates declined 2.2% per year (95% CI, 1.8% to 2.6%) from 1988 to 2004 in the SFBA and the rest of California. Use of estrogen-progestin hormone therapy decreased significantly from 2001 to 2003 in both regions. In 2003–2004, invasive breast cancer incidence remained higher (4.2%) in the SFBA than in the rest of California, consistent with the higher distributions of many established risk factors, including advanced education, nulliparity, late age at first birth, and alcohol consumption.

Conclusion

Ongoing surveillance of breast cancer occurrence patterns in this high-risk population informs breast cancer etiology through comparison of trends with lower-risk populations and by highlighting the importance of examining how broad migration patterns influence the geographic distribution of risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, (Eds): Cancer Incidence in Five Continents, Vol. VIII, Vol. 155. 2002, Lyon, France: IARC Scientific Publications Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, (Eds): Cancer Incidence in Five Continents, Vol. VIII, Vol. 155. 2002, Lyon, France: IARC Scientific Publications
3.
go back to reference Clarke CA, Glaser SL, West DW, Ereman RR, Erdmann CA, Barlow JM, Wrensch MR: Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999. Breast Cancer Res. 2002, 4: R13-10.1186/bcr458.CrossRefPubMedPubMedCentral Clarke CA, Glaser SL, West DW, Ereman RR, Erdmann CA, Barlow JM, Wrensch MR: Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999. Breast Cancer Res. 2002, 4: R13-10.1186/bcr458.CrossRefPubMedPubMedCentral
4.
go back to reference Prehn A, Clarke C, Topol B, Glaser S, West D: Increase in breast cancer incidence in middle-aged women during the 1990s. Ann Epidemiol. 2002, 12: 476-481. 10.1016/S1047-2797(01)00315-5.CrossRefPubMed Prehn A, Clarke C, Topol B, Glaser S, West D: Increase in breast cancer incidence in middle-aged women during the 1990s. Ann Epidemiol. 2002, 12: 476-481. 10.1016/S1047-2797(01)00315-5.CrossRefPubMed
5.
go back to reference Prehn AW, West DW: Evaluating local differences in breast cancer incidence rates: a census-based methodology (United States). Cancer Causes Control. 1998, 9: 511-517. 10.1023/A:1008809819218.CrossRefPubMed Prehn AW, West DW: Evaluating local differences in breast cancer incidence rates: a census-based methodology (United States). Cancer Causes Control. 1998, 9: 511-517. 10.1023/A:1008809819218.CrossRefPubMed
6.
go back to reference Laden F, Spiegelman D, Neas LM, Colditz GA, Hankinson SE, Manson JE, Byrne C, Rosner BA, Speizer FE, Hunter DJ: Geographic variation in breast cancer incidence rates in a cohort of U.S. women. J Natl Cancer Inst. 1997, 89: 1373-1378. 10.1093/jnci/89.18.1373.CrossRefPubMed Laden F, Spiegelman D, Neas LM, Colditz GA, Hankinson SE, Manson JE, Byrne C, Rosner BA, Speizer FE, Hunter DJ: Geographic variation in breast cancer incidence rates in a cohort of U.S. women. J Natl Cancer Inst. 1997, 89: 1373-1378. 10.1093/jnci/89.18.1373.CrossRefPubMed
7.
go back to reference Reynolds P, Hurley SE, Quach AT, Rosen H, Von Behren J, Hertz A, Smith D: Regional variations in breast cancer incidence among California women, 1988–1997. Cancer Causes Control. 2005, 16: 139-150. 10.1007/s10552-004-2616-5.CrossRefPubMed Reynolds P, Hurley SE, Quach AT, Rosen H, Von Behren J, Hertz A, Smith D: Regional variations in breast cancer incidence among California women, 1988–1997. Cancer Causes Control. 2005, 16: 139-150. 10.1007/s10552-004-2616-5.CrossRefPubMed
8.
go back to reference Robbins AS, Brescianini S, Kelsey JL: Regional differences in known risk factors and the higher incidence of breast cancer in San Francisco. J Natl Cancer Inst. 1997, 89: 960-965. 10.1093/jnci/89.13.960.CrossRefPubMed Robbins AS, Brescianini S, Kelsey JL: Regional differences in known risk factors and the higher incidence of breast cancer in San Francisco. J Natl Cancer Inst. 1997, 89: 960-965. 10.1093/jnci/89.13.960.CrossRefPubMed
9.
go back to reference Census 2000 Summary File 3, Matrices P19, P36, P37, P38, PCT24, and PCT25. Census 2000 Summary File 3, Matrices P19, P36, P37, P38, PCT24, and PCT25.
10.
go back to reference Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24: e49-50. 10.1200/JCO.2006.08.6504.CrossRefPubMed Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24: e49-50. 10.1200/JCO.2006.08.6504.CrossRefPubMed
11.
go back to reference Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2007, Apr 24, Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2007, Apr 24,
12.
go back to reference Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.CrossRefPubMed Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.CrossRefPubMed
13.
go back to reference Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007, 9: R28-10.1186/bcr1672.CrossRefPubMedPubMedCentral Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007, 9: R28-10.1186/bcr1672.CrossRefPubMedPubMedCentral
14.
go back to reference Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
15.
go back to reference Fritz A, Percy C, Jack A, Kanagaratnam K, Sobin L, Parkin DM, Whelan S, (Eds): International Classification of Diseases for Oncology. 2000, Geneva, Switzerland: World Health Organization, 3 Fritz A, Percy C, Jack A, Kanagaratnam K, Sobin L, Parkin DM, Whelan S, (Eds): International Classification of Diseases for Oncology. 2000, Geneva, Switzerland: World Health Organization, 3
16.
go back to reference Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21: 28-34. 10.1200/JCO.2003.03.088.CrossRefPubMed Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21: 28-34. 10.1200/JCO.2003.03.088.CrossRefPubMed
17.
go back to reference Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002, 11: 601-607.PubMed Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002, 11: 601-607.PubMed
18.
go back to reference Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005, 93: 1046-1052. 10.1038/sj.bjc.6602787.CrossRefPubMedPubMedCentral Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005, 93: 1046-1052. 10.1038/sj.bjc.6602787.CrossRefPubMedPubMedCentral
19.
go back to reference Miller BA, Hankey BF, Thomas TL: Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol. 2002, 155: 534-545. 10.1093/aje/155.6.534.CrossRefPubMed Miller BA, Hankey BF, Thomas TL: Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol. 2002, 155: 534-545. 10.1093/aje/155.6.534.CrossRefPubMed
20.
go back to reference Tarone RE, Chu KC: The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control. 2002, 13: 7-14. 10.1023/A:1013960609008.CrossRefPubMed Tarone RE, Chu KC: The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control. 2002, 13: 7-14. 10.1023/A:1013960609008.CrossRefPubMed
21.
go back to reference Gomez SL, Le GM, West DW, Satariano WA, O'Connor L: Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health. 2003, 93: 1685-1688.CrossRefPubMedPubMedCentral Gomez SL, Le GM, West DW, Satariano WA, O'Connor L: Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health. 2003, 93: 1685-1688.CrossRefPubMedPubMedCentral
22.
go back to reference Ingram DD, Parker JD, Schenker N, Weed JA, Hamilton B, Arias E, Madans JH: United States Census 2000 population with bridged race categories. Vital Health Stat 2. 2003, 1-55. 135 Ingram DD, Parker JD, Schenker N, Weed JA, Hamilton B, Arias E, Madans JH: United States Census 2000 population with bridged race categories. Vital Health Stat 2. 2003, 1-55. 135
23.
go back to reference Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, Erdmann CA, Lee M, Moghadassi M, Peskin-Mentzer R, et al: Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res. 2003, 5: R88-102. 10.1186/bcr605.CrossRefPubMedPubMedCentral Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, Erdmann CA, Lee M, Moghadassi M, Peskin-Mentzer R, et al: Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res. 2003, 5: R88-102. 10.1186/bcr605.CrossRefPubMedPubMedCentral
24.
go back to reference John EM, Horn-Ross PL, Koo J: Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev. 2003, 12 (11 Pt 1): 1143-1152.PubMed John EM, Horn-Ross PL, Koo J: Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev. 2003, 12 (11 Pt 1): 1143-1152.PubMed
25.
go back to reference Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF: Reproductive factors in Hodgkin's disease in women. Am J Epidemiol. 2003, 158: 553-563. 10.1093/aje/kwg198.CrossRefPubMed Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF: Reproductive factors in Hodgkin's disease in women. Am J Epidemiol. 2003, 158: 553-563. 10.1093/aje/kwg198.CrossRefPubMed
26.
go back to reference Horn-Ross PL, Morris JS, Lee M, West DW, Whittemore AS, McDougall IR, Nowels K, Stewart SL, Spate VL, Shiau AC, et al: Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001, 10: 979-985.PubMed Horn-Ross PL, Morris JS, Lee M, West DW, Whittemore AS, McDougall IR, Nowels K, Stewart SL, Spate VL, Shiau AC, et al: Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001, 10: 979-985.PubMed
27.
go back to reference California Health Interview Survey. CHIS 2001 Methodology Series: Report 4-Response Rates. Edited by: Survey CHI. 2002, Los Angeles, CA: UCLA Center for Health Policy Research California Health Interview Survey. CHIS 2001 Methodology Series: Report 4-Response Rates. Edited by: Survey CHI. 2002, Los Angeles, CA: UCLA Center for Health Policy Research
28.
go back to reference California Health Interview Survey. CHIS 2003 Methodology Series: Report 4-Response Rates. Edited by: Survey CHI. 2005, Los Angeles, CA: UCLA Center for Health Policy Research, California Health Interview Survey. CHIS 2003 Methodology Series: Report 4-Response Rates. Edited by: Survey CHI. 2005, Los Angeles, CA: UCLA Center for Health Policy Research,
29.
go back to reference California Health Interview Survey. The CHIS 2001 Sample: Response Rate and Representativeness. Edited by: Survey CHI. 2003, Los Angeles, CA: UCLA Center for Health Policy Research California Health Interview Survey. The CHIS 2001 Sample: Response Rate and Representativeness. Edited by: Survey CHI. 2003, Los Angeles, CA: UCLA Center for Health Policy Research
30.
go back to reference Colditz GA, Baer HJ, Tamimi RM: Breast cancer. Cancer Epidemiology and Prevention. Edited by: Schottenfeld D, Fraumeni JF Jr. 2006, Oxford, UK: Oxford University Press, 995-1012. 3CrossRef Colditz GA, Baer HJ, Tamimi RM: Breast cancer. Cancer Epidemiology and Prevention. Edited by: Schottenfeld D, Fraumeni JF Jr. 2006, Oxford, UK: Oxford University Press, 995-1012. 3CrossRef
33.
go back to reference Kleinbaum D, Kupper L, Muller K: Applied Regression Analysis and Other Multivariable Methods. 1988, Boston, MA: PWS-Kent, 2 Kleinbaum D, Kupper L, Muller K: Applied Regression Analysis and Other Multivariable Methods. 1988, Boston, MA: PWS-Kent, 2
34.
go back to reference Joinpoint Regression Program. Statistical Research and Applications Branch, National Cancer Institute. 2005, 3.0 Joinpoint Regression Program. Statistical Research and Applications Branch, National Cancer Institute. 2005, 3.0
36.
go back to reference Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996, 275: 370-375. 10.1001/jama.275.5.370. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996, 275: 370-375. 10.1001/jama.275.5.370.
37.
go back to reference Centers for Disease Control and Prevention (CDC): Decline in breast cancer incidence – United States, 1999–2003. MMWR Morb Mortal Wkly Rep. 2007, 56: 549-553. Centers for Disease Control and Prevention (CDC): Decline in breast cancer incidence – United States, 1999–2003. MMWR Morb Mortal Wkly Rep. 2007, 56: 549-553.
38.
go back to reference Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.CrossRefPubMed Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.CrossRefPubMed
39.
go back to reference Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004, 140: 184-188.CrossRefPubMed Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004, 140: 184-188.CrossRefPubMed
40.
go back to reference Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.CrossRefPubMed Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.CrossRefPubMed
41.
go back to reference Wun LM, Feuer EJ, Miller BA: Are increases in mammographic screening still a valid explanation for trends in breast cancer incidence in the United States?. Cancer Causes Control. 1995, 6: 135-144. 10.1007/BF00052774.CrossRefPubMed Wun LM, Feuer EJ, Miller BA: Are increases in mammographic screening still a valid explanation for trends in breast cancer incidence in the United States?. Cancer Causes Control. 1995, 6: 135-144. 10.1007/BF00052774.CrossRefPubMed
42.
go back to reference Maskarinec G, Wilkens L, Meng L: Mammography screening and the increase in breast cancer incidence in Hawaii. Cancer Epidemiol Biomarkers Prev. 1997, 6: 201-208.PubMed Maskarinec G, Wilkens L, Meng L: Mammography screening and the increase in breast cancer incidence in Hawaii. Cancer Epidemiol Biomarkers Prev. 1997, 6: 201-208.PubMed
44.
go back to reference Frey W: Metro America in the new century: metropolitan and central city demographic shifts since 2000. Metropolitan Policy Program, Living Cities Census Series. 2005, Washington, D.C.: The Brookings Institute Frey W: Metro America in the new century: metropolitan and central city demographic shifts since 2000. Metropolitan Policy Program, Living Cities Census Series. 2005, Washington, D.C.: The Brookings Institute
45.
go back to reference Mack T: Cancers in the Urban Environment. 2004, London, UK: Elsevier Academic Press Mack T: Cancers in the Urban Environment. 2004, London, UK: Elsevier Academic Press
46.
go back to reference Yost K, Perkins C, Cohen R, Morris C, Wright W: Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001, 12: 703-711. 10.1023/A:1011240019516.CrossRefPubMed Yost K, Perkins C, Cohen R, Morris C, Wright W: Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001, 12: 703-711. 10.1023/A:1011240019516.CrossRefPubMed
47.
go back to reference Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, et al: High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control. 2002, 13: 625-635. 10.1023/A:1019552126105.CrossRefPubMed Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, et al: High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control. 2002, 13: 625-635. 10.1023/A:1019552126105.CrossRefPubMed
48.
go back to reference Robert SA, Strombom I, Trentham-Dietz A, Hampton JM, McElroy JA, Newcomb PA, Remington PL: Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology. 2004, 15: 442-450. 10.1097/01.ede.0000129512.61698.03.CrossRefPubMed Robert SA, Strombom I, Trentham-Dietz A, Hampton JM, McElroy JA, Newcomb PA, Remington PL: Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology. 2004, 15: 442-450. 10.1097/01.ede.0000129512.61698.03.CrossRefPubMed
Metadata
Title
Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004
Authors
Theresa HM Keegan
Ellen T Chang
Esther M John
Pamela L Horn-Ross
Margaret R Wrensch
Sally L Glaser
Christina A Clarke
Publication date
01-10-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1768

Other articles of this Issue 5/2007

Breast Cancer Research 5/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine